GD2-CART01 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Medulloblastoma.

SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

LAE-005 (FAZ-053) is under development for the treatment of advanced solid tumors including chordoma, alveolar soft part sarcoma, triple negative breast cancer. It is administered through intravenous ...

Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Oropharyngeal Cancer.

Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Polycystic Ovarian Syndrome.

Trilaciclib is under clinical development by Pharmacosmos and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified B-Cell Lymphomas.

Fosfomycin disodium is under clinical development by Meitheal Pharmaceuticals and currently in Pre-Registration for Urinary Tract Infections.

KH-903 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase II for Metastatic Colorectal Cancer.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...